comparemela.com

Latest Breaking News On - Key starting material - Page 1 : comparemela.com

India s import of Active Pharmaceutical Ingredients and Key Starting Material from other countries including China grew: Ministry

India s import of Active Pharmaceutical Ingredients and Key Starting Material from other countries including China grew: Ministry
thehindu.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindu.com Daily Mail and Mail on Sunday newspapers.

Pharma sector hits upon right formula - The Hindu BusinessLine

Pharma sector hits upon right formula - The Hindu BusinessLine
thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.

Indian gov t waives off import duty on antiviral drug amid COVID-19 spike - World News

2021-04-21 10:06:07 GMT2021-04-21 18:06:07(Beijing Time) Xinhua English NEW DELHI, April 21 (Xinhua) India s federal government Wednesday announced that it has waived off the import duty on Remdesivir, a broad-spectrum antiviral drug, to provide affordable medical care for the COVID-19 patients, officials said. The step is aimed at increasing the supply of the drug and reduce the cost which will benefit the patients. A notification issued by the federal finance ministry said import duty was removed from Remdesivir active pharmaceutical ingredients, injection and specific substances used in the manufacture of Remdesivir. Considering the immediate requirement on the recommendation of the Department of Pharmaceuticals, the Department of Revenue has waived customs duty on Remdesivir and its Active Pharmaceutical Ingredients (API)/Key Starting Material (KSM). This step will further augment domestic availability of Remdesivir injection, Minister of Chemicals and Fertilizers

Budget 2021 Expectations: Pharma Industry Seeks Steps To Reduce Dependence On API Imports From China

Budget 2021 expectations: Pharma industry seeks steps to reduce dependence on API imports from China It is expected that the government will continue to focus on reduced import dependence, and encourage investments to boost R&D and capital expenditure. January 08, 2021 / 10:06 PM IST With the Union Budget for FY2022 to be presented in a few days, the pharmaceutical and API industry expects a few supportive announcements from the government that will boost growth. It is expected that the government will continue to focus on reduced import dependence, encourage investments to boost R&D, and capital expenditure. Some of the specific areas that are likely to receive attention in the Union Budget 2021 are reducing dependence on API supplies from China, providing impetus to R&D through higher tax deductions and reducing GST rates for life saving and essential drugs.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.